Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28549731 | 0.98 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2MAPK1 | |
| SCHEMBL23292189 | 0.84 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL28550615 | 0.83 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5865018 | 0.82 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL708399 | 0.82 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2MAPK1 | |
| SCHEMBL8816520 | 0.81 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL28387134 | 0.80 | TAAR1 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2MAPK1 | |
| SCHEMBL7848052 | 0.80 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2MAPK1 | |
| SCHEMBL30563707 | 0.80 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2MAPK1 | |
| SCHEMBL8168666 | 0.80 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117247403-A | Push-pull type silicon-containing asymmetric Mirabilite derivative heptamethine chromophore compound, composite material, thin film and photoelectric integrated device | 香港城市大学深圳研究院 | 2023-12-19 | — | — | CN | claimed |
| EP-2948455-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | Euroscreen S.A. (BE) | 2015-12-02 | — | — | EP | claimed |
| WO-2014154895-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | EUROSCREEN SA (BE) | 2014-10-02 | — | — | WO | claimed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| EP-0378604-B1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES | ERBA CARLO SPA (IT) | 1994-03-02 | — | — | EP | claimed |
| EP-0378604-A1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES. | ERBA CARLO SPA (IT) | 1990-07-25 | — | — | EP | claimed |
| WO-1989010926-A1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-11-16 | — | — | WO | claimed |
| EP-3813946-B1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-22 | — | — | EP | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-4302827-A2 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN Pharmaceutica NV (BE) | 2024-01-10 | — | — | EP | disclosed |
| CN-117247403-A | Push-pull type silicon-containing asymmetric Mirabilite derivative heptamethine chromophore compound, composite material, thin film and photoelectric integrated device | 香港城市大学深圳研究院 | 2023-12-19 | — | — | CN | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
| EP-0378604-B1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES | ERBA CARLO SPA (IT) | 1994-03-02 | — | — | EP | disclosed |
| EP-0378604-A1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES. | ERBA CARLO SPA (IT) | 1990-07-25 | — | — | EP | disclosed |
| WO-1989010926-A1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-11-16 | — | — | WO | disclosed |
| US-4684641-A | BACTERICIDES | PFIZER INC. (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0168177-A2 | Cephalosporin antibiotics | Pfizer Limited (GB) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMYD2 1418/4885CYP3A4 4739/4885HTT 2514/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMYD2 1418/4885CYP3A4 4739/4885HTT 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.